Genzyme offer may hit B
Sanofi-Aventis SA Chief Executive Officer Chris Viehbacher has support from his board of directors to offer as much as $ 70 a share for Genzyme Corp., or about $ 18.7 billion, said three people with knowledge of the situation.
Read more on Worcester Telegram & Gazette
Celgene Q2 Profit Tops View On Strong Revlimid, Vidaza Sales; Raises Full-year Forecast – Update
Biopharmaceutical company Celgene Corp. reported Thursday a market-beating performance for the second quarter, helped by strong sales growth from its cancer drugs Revlimid and Vidaza. The Summit, New Jersey-based company also lifted its full year adjusted earnings and revenue forecast.
Celgene Q2 Profit Tops View On Strong Revlimid, Vidaza Sales; Raises Full-year Forecast – Update
Biopharmaceutical company Celgene Corp. reported Thursday a market-beating performance for the second quarter, helped by strong sales growth from its cancer drugs Revlimid and Vidaza. The Summit, New Jersey-based company also lifted its full year adjusted earnings and revenue forecast.
Read more on RTT News
Related posts:
- Sanofi-Aventis, Genzyme discuss possible acquisition: Wall Street Journal
- Merck’s 2Q net drops on higher costs, charges
- Cialis fuels Lilly’s men’s health drug sales
- GTC Biotherapeutics regains US commercialization rights to ATryn from Lundbeck
- Latest “nexium” News